Editorial note: This educational article is based on established medical information from reputable U.S. clinical resources, including ACP/MKSAP-style case reasoning, NIH/MedlinePlus, Mayo Clinic, Parkinson’s Foundation, Johns Hopkins Medicine, APDA, and peer-reviewed neurology literature. It is for general education only and is not a substitute for professional medical advice.
Introduction: When Parkinson Treatment Starts Playing Hide-and-Seek
A 68-year-old man with Parkinson disease walks into a follow-up visitnot quite the start of a joke, but definitely the start of a classic internal medicine teaching moment. He was diagnosed 10 years ago, initially responded well to medication, and for a while his treatment worked like a reliable morning coffee: predictable, comforting, and absolutely necessary. But over the past few years, things have become less tidy. His tremor and slowness return before the next dose is due, his medication benefit lasts only a short time, and increasing levodopa brings unwanted side effects such as visual hallucinations and troublesome involuntary movements.
This is the kind of scenario that makes MKSAP questions so valuable. They do not simply ask, “What is Parkinson disease?” They ask, “What do you do when the usual Parkinson disease treatment still worksbut not long enough, not smoothly enough, and not safely enough?” That is a much more interesting question. It is also where advanced Parkinson disease management moves beyond simply adding another pill to the stack and hoping the medication cabinet does not need its own zip code.
The central issue in this case is motor complications in advanced Parkinson disease: wearing-off, dyskinesia, and medication-limited treatment. The best answer is not more of the same. In a patient who still responds clearly to levodopa but has disabling fluctuations and medication-induced complications, deep brain stimulation, often shortened to DBS, becomes an important treatment option.
Understanding Parkinson Disease in a 68-Year-Old Patient
Parkinson disease is a progressive neurodegenerative movement disorder. Its classic motor features include bradykinesia, resting tremor, rigidity, and later problems with posture and gait. Bradykinesia means slowness of movement, but in real life it often looks like taking forever to button a shirt, struggling to rise from a chair, or needing several small steps to turn around. Resting tremor often begins on one side of the body and improves with purposeful movement. Rigidity can feel like stiffness that refuses to loosen up, no matter how politely the patient asks.
The disease is strongly linked to loss of dopamine-producing neurons in the substantia nigra, a deep brain region involved in movement control. Dopamine is not the whole story, but it is the main character in the motor-symptom plot. When dopamine signaling falls, movement becomes slower, stiffer, and less coordinated. That is why dopaminergic therapies, especially carbidopa-levodopa, are central to Parkinson disease treatment.
In older adults, Parkinson disease rarely stays limited to tremor. Non-motor symptoms may include constipation, sleep disturbance, depression, anxiety, urinary symptoms, orthostatic hypotension, fatigue, cognitive changes, and hallucinations. These symptoms can be just as disabling as the motor symptoms. A patient may say, “My tremor is annoying,” but what truly ruins the day might be freezing in the doorway, falling, not sleeping, or seeing things that are not there after a medication increase.
The MKSAP Teaching Point: Levodopa Still Works, But the Window Is Narrow
The key clue in this case is that the patient improves after taking carbidopa-levodopa. His bradykinesia, rigidity, and gait get better when the medicine is active. That tells us his motor symptoms are still levodopa-responsive. In Parkinson disease, levodopa responsiveness is an important marker because symptoms that improve with levodopa are often the same symptoms most likely to improve with deep brain stimulation.
However, the benefit lasts only a short time. This is called wearing-off. Instead of one dose carrying the patient smoothly to the next dose, symptoms return early. A person may feel reasonably mobile at 9 a.m., stiff and shaky by 11 a.m., better again after another dose, and then off again before lunch has even had a chance to be emotionally supportive.
The second clue is dyskinesia. Dyskinesias are involuntary, often flowing or writhing movements that can appear when levodopa levels peak. They are different from tremor. Tremor is usually rhythmic and often occurs at rest; dyskinesia may look like twisting, fidgeting, rocking, or dance-like movement. Some patients prefer mild dyskinesia over being frozen and immobile, but severe dyskinesia can be exhausting, embarrassing, and unsafe.
The third clue is hallucinations with higher doses of levodopa. Visual hallucinations in Parkinson disease may occur because of the disease itself, medication effects, sleep disturbance, cognitive vulnerability, or a combination of factors. In this case, higher dopaminergic dosing worsens hallucinations, limiting how aggressively medication can be increased. That is the clinical trap: the patient needs more reliable motor control, but more medication creates unacceptable side effects.
Why Deep Brain Stimulation Is the Best Fit
Deep brain stimulation is an advanced treatment for selected patients with Parkinson disease. It involves placing thin electrodes into specific brain targets, commonly the subthalamic nucleus or globus pallidus internus, and connecting them to an implanted pulse generator. The device sends controlled electrical signals that help regulate abnormal motor circuitry. The simple version: DBS is like installing a highly sophisticated dimmer switch for misfiring movement circuits. It is not magic, but when used in the right patient, it can look impressively close.
DBS is not a cure. It does not stop Parkinson disease from progressing, replace lost neurons, or make a 68-year-old suddenly moonwalk through the clinic. What it can do is reduce medication-responsive motor symptoms, smooth out motor fluctuations, reduce off time, and allow lower medication doses. Lower medication doses may also reduce medication-induced dyskinesia and hallucinations in carefully selected patients.
Why This Patient Is a Strong DBS Candidate
This patient has several features that support DBS consideration. First, he has advanced Parkinson disease with disabling motor fluctuations. Second, he continues to respond well to levodopa, which predicts that DBS may help his motor symptoms. Third, he has medication-induced complications that limit further medical adjustment. Fourth, his cognitive assessment is normal, which matters because significant dementia is a major concern when considering DBS.
DBS is most useful when the main problem is not that medications have stopped working entirely, but that they work unpredictably or cause side effects. In this patient, levodopa still opens the door to better movement, but the door slams shut too soon and sometimes knocks over the furniture on the way out. DBS helps widen the therapeutic window.
Why the Other Options Are Less Appropriate
Discontinuing Entacapone
Entacapone is a COMT inhibitor. It helps extend the effect of levodopa by reducing its breakdown. Stopping entacapone might reduce dyskinesia in some patients, but it can also worsen wearing-off because levodopa will not last as long. In a patient whose main complaint is that medication benefit already disappears too quickly, removing an extender is like taking away the umbrella because the rain is annoying.
Increasing Amantadine
Amantadine can help reduce levodopa-induced dyskinesia, and it has a real role in Parkinson disease management. But in older adults, and especially in someone already experiencing hallucinations, increasing amantadine can worsen confusion, hallucinations, edema, and other side effects. It may treat one problem while pouring gasoline on another. That is not elegant medicine; that is medication whack-a-mole.
Adding Ropinirole
Ropinirole is a dopamine agonist. It can improve motor symptoms and reduce off time in some patients, but dopamine agonists are often harder to tolerate in older adults. They can worsen hallucinations, sleepiness, orthostatic hypotension, leg swelling, and impulse-control behaviors such as compulsive gambling or shopping. In this case, adding ropinirole would likely intensify the very complications that are already limiting treatment.
Adding Selegiline
Selegiline is an MAO-B inhibitor that can modestly prolong dopaminergic activity. It may be useful in selected patients, especially earlier or milder cases. But when dyskinesia is already prominent, adding another medication that increases dopaminergic tone may worsen involuntary movements. It is not the strongest choice for a patient who has advanced motor fluctuations plus medication-induced complications.
Motor Fluctuations: The “On-Off” Roller Coaster
Motor fluctuations are one of the most important concepts in advanced Parkinson disease. Early in treatment, levodopa may provide smooth symptom relief for hours. Over time, as the disease progresses, the brain loses some ability to store and buffer dopamine. Medication response becomes more dependent on each dose. The patient begins to cycle between “on” periods, when movement is better, and “off” periods, when tremor, slowness, rigidity, or freezing return.
Wearing-off is usually predictable at first. The patient knows symptoms return before the next dose. Later, fluctuations may become less predictable. Some doses kick in slowly. Some fail. Some work beautifully, then suddenly stop. Meals, protein intake, constipation, delayed gastric emptying, sleep quality, and stress can all affect response. Parkinson disease, apparently, did not receive the memo about being convenient.
When motor fluctuations become disabling, clinicians may adjust levodopa timing, use extended-release formulations, add COMT inhibitors, add MAO-B inhibitors, consider amantadine for dyskinesia, or use device-assisted therapies. The right choice depends on the patient’s symptoms, age, cognition, psychiatric history, fall risk, medication tolerance, and personal goals.
Dyskinesia: When Treatment Creates a New Movement Problem
Dyskinesia is a common long-term complication of levodopa therapy. It often appears when levodopa levels are highest, although patterns vary. Some patients have peak-dose dyskinesia, some have diphasic dyskinesia as medication levels rise or fall, and some experience off-period dystonia, such as painful foot cramping in the morning.
The difficult part is that dyskinesia is tied to the same medication that improves mobility. Reducing levodopa may reduce dyskinesia but worsen stiffness and slowness. Increasing levodopa may improve off time but worsen dyskinesia. Clinicians often balance these tradeoffs by adjusting dose size, dose frequency, adjunct medications, and daily routines. When the balance becomes impossible, DBS becomes more attractive.
For this patient, dyskinesia appears when medication is working, while disabling Parkinson symptoms return when medication wears off. This creates a narrow therapeutic window. DBS can help by improving motor control and reducing the need for high dopaminergic doses.
Hallucinations in Parkinson Disease: A Red Flag in Medication Planning
Visual hallucinations in Parkinson disease deserve careful attention. They may begin as mild illusions, such as mistaking a shadow for a person, and progress to well-formed images. Some patients retain insight and know the image is not real; others may become frightened or confused. Hallucinations can increase caregiver stress and may signal vulnerability to cognitive decline or medication intolerance.
When hallucinations occur, clinicians review medications carefully. Drugs with anticholinergic effects, dopamine agonists, amantadine, MAO-B inhibitors, COMT inhibitors, and high-dose levodopa can all contribute. The usual strategy is to simplify therapy when possible, treat infections or metabolic triggers, improve sleep, and avoid dopamine-blocking antipsychotics that can worsen Parkinson symptoms. In selected cases, Parkinson-specific psychosis treatment may be considered.
In this MKSAP-style scenario, hallucinations limit further levodopa escalation. That makes DBS more reasonable because it may permit medication reduction while preserving motor benefit.
What DBS Can and Cannot Do
DBS Can Help
DBS can improve tremor, rigidity, bradykinesia, motor fluctuations, and dyskinesia in properly selected patients. It can reduce off time and increase good on time. It can also allow reduction in dopaminergic medication, which may reduce medication-related side effects. Many patients describe feeling more predictable during the day, which is a quality-of-life improvement that does not always show up neatly in a lab result.
DBS Usually Cannot Help
DBS is less reliable for symptoms that do not respond to levodopa. These may include severe balance problems, freezing that does not improve with medication, speech impairment, swallowing difficulty, dementia, and many autonomic symptoms. DBS also does not cure depression, constipation, or the need to plan one’s day around medication timing, although it may make the planning less dramatic.
DBS Requires Follow-Up
DBS is not a “set it and forget it” procedure. After surgery, patients need programming visits to adjust stimulation settings. Medications may need to be reduced or retimed. Batteries eventually need replacement or recharging depending on the device. Good outcomes depend on a multidisciplinary team that may include a movement disorders neurologist, neurosurgeon, neuropsychologist, psychiatrist, physical therapist, speech therapist, and primary care clinician.
How Clinicians Evaluate a Patient for DBS
A DBS evaluation usually begins with confirming the diagnosis. Parkinson disease must be distinguished from atypical parkinsonism, such as progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome, or dementia with Lewy bodies. These conditions may respond poorly to DBS and often have early gait, autonomic, eye movement, or cognitive features that point away from typical Parkinson disease.
Next comes levodopa-response testing. The patient is examined in an off-medication state and again after medication. If motor symptoms improve significantly, that supports DBS candidacy. Neuropsychological testing is also important because significant cognitive impairment increases risk and may reduce benefit. Psychiatric conditions, especially unstable depression, anxiety, psychosis, or impulse-control problems, should be addressed before surgery.
The team also discusses expectations. A good candidate understands that DBS can improve specific symptoms but will not restore perfect health. The goal is better function, fewer disabling off periods, less dyskinesia, and improved quality of lifenot turning back the clock to age 42 with a tennis racket and suspiciously good knees.
Practical Example: A Day Before and After Better Control
Before advanced treatment, a patient like this may wake stiff and slow, take levodopa, wait for it to kick in, enjoy a brief window of better movement, and then experience wearing-off before the next dose. He may hesitate before walking across a room, struggle with handwriting, need help with buttons, and time errands around medication peaks. If the dose is increased, dyskinesia and hallucinations may appear. The patient is stuck between being under-treated and over-treated.
After successful DBS programming and medication adjustment, the same patient may still have Parkinson disease, but the day can become more predictable. Off periods may shorten. Dyskinesias may decrease. Tremor and rigidity may become easier to manage. Medication doses may be lower. The patient may regain confidence with daily routines such as eating, dressing, walking around the house, or going out with family. The improvement may not be cinematic, but in chronic disease care, “I can get through breakfast without a crisis” is a blockbuster.
Patient Safety: Medication Timing, Falls, and Communication
Advanced Parkinson disease care is not only about choosing DBS or medications. It is also about preventing avoidable complications. Medication timing is crucial. Hospitalized patients with Parkinson disease should receive medications on their home schedule whenever possible, because delayed doses can cause severe immobility, rigidity, swallowing problems, aspiration risk, and distress.
Fall prevention is equally important. Physical therapy can help with gait training, balance strategies, cueing techniques, and home safety. Occupational therapy can recommend adaptive tools for dressing, eating, bathing, and writing. Speech therapy can help with voice volume, swallowing safety, and communication. Nutrition support may help with constipation, weight loss, hydration, and protein-medication timing.
Caregiver education matters too. Families should know the difference between off periods, dyskinesia, hallucinations, delirium, and medication side effects. They should also know when to call the clinician: sudden worsening, new confusion, falls, swallowing problems, fever, fainting, or dramatic hallucinations should never be brushed aside as “just Parkinson’s.”
Board-Style Takeaway for the MKSAP Question
The most appropriate treatment in this case is deep brain stimulation. The reason is not simply that the patient has Parkinson disease. Many people with Parkinson disease are not DBS candidates. The reason is that he has advanced, levodopa-responsive Parkinson disease with disabling motor fluctuations and medication-induced complications that limit further medical therapy. His normal cognitive assessment also supports consideration of DBS.
The wrong answers are tempting because each medication has a legitimate role somewhere in Parkinson care. Entacapone helps wearing-off. Amantadine can help dyskinesia. Ropinirole can improve dopaminergic stimulation. Selegiline can extend dopamine activity. But medicine is not about knowing what a drug can do in theory; it is about knowing whether it helps this patient in this situation. Here, adding or increasing dopaminergic therapy risks worsening hallucinations and dyskinesia. Removing entacapone risks worsening off time. DBS addresses the pattern more directly.
Experience-Based Reflections: What This Case Feels Like in Real Life
For patients and families, the most frustrating part of advanced Parkinson disease is often not one single symptom. It is the unpredictability. One hour, the patient can walk into the kitchen and make toast. Two hours later, the same kitchen feels like an obstacle course designed by a mischievous neurologist. A doorway becomes a freezing trigger. A shirt button becomes an engineering challenge. A spoonful of soup becomes a slow-motion negotiation between tremor, stiffness, and pride.
Families may initially think the patient is “having a good day” or “having a bad day,” but advanced Parkinson disease can create good and bad hours within the same day. That is why medication diaries are so useful. A simple log noting dose times, on periods, off periods, dyskinesia, hallucinations, meals, sleep, and falls can reveal patterns that a rushed appointment might miss. Patients often underestimate how much information they carry in their daily routines. The diary turns lived experience into clinical evidence.
Another real-world lesson is that dyskinesia can be misunderstood. To an observer, extra movement may look like nervous energy or agitation. To the patient, it may feel like the price paid for being able to move at all. Some patients say, “I would rather wiggle than freeze.” Others find dyskinesia exhausting or socially embarrassing. There is no universal answer. Good care asks what matters most to the person living inside the symptoms.
Hallucinations can be especially delicate. Patients may hide them because they fear being labeled “crazy” or losing independence. A calm, nonjudgmental question helps: “Have you ever seen people, animals, shadows, or shapes that others did not see?” If the answer is yes, the clinician can explore timing, insight, medication changes, sleep, infection, and safety. The goal is not to shame the patient; the goal is to protect them.
DBS discussions also require emotional honesty. Some patients hear “brain surgery” and immediately imagine the worst. Others hear “device” and expect a cure. The best conversations live in the middle. DBS can be life-changing for the right candidate, but it requires testing, surgery, programming, follow-up, and realistic expectations. The patient should understand what symptoms are likely to improve and what symptoms may not. If balance, dementia, or swallowing problems are the main issues, DBS may disappoint. If levodopa-responsive tremor, rigidity, bradykinesia, wearing-off, and dyskinesia are the main issues, DBS may be a very reasonable next step.
The practical experience of this MKSAP case is a reminder that advanced Parkinson disease care is not about chasing perfect movement. It is about preserving dignity, independence, safety, and predictability. Sometimes the best treatment is not another dose, but a smarter strategy. And sometimes the most important question is not “What medicine can we add?” but “Has this patient reached the point where advanced therapy offers a better balance than more medication?”
Conclusion
The case of a 68-year-old man with Parkinson disease highlights a classic advanced-treatment decision. He has levodopa-responsive symptoms, but the benefit wears off quickly. Higher medication doses trigger hallucinations, and peak-dose dyskinesia appears when treatment is active. In this setting, deep brain stimulation is the most appropriate option because it targets medication-responsive motor complications while potentially allowing medication reduction.
The broader lesson is simple: Parkinson disease treatment must evolve as the disease evolves. Early success with carbidopa-levodopa does not guarantee long-term smooth control. When wearing-off, dyskinesia, and medication side effects collide, clinicians should think beyond routine dose escalation. DBS is not for everyone, but for the carefully selected patient, it can turn an unpredictable day into a more manageable one. And in Parkinson care, manageable is not a small victoryit is the whole point.
